Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
Find out how Optimi Health’s UK psilocybin export could reshape psychedelic trial supply and what risks remain for Phase 2 research.
Why Psyence Biomedical Ltd.’s Australian trial strategy could shape global psychedelic drug development pathways
Psyence Biomedical Ltd. advances NPX-5 dosing in Australia. Discover how this trial strategy could shape global psychedelic drug development.
Why Compass Pathways’ upcoming COMP360 data could redefine late-stage psychedelic drug development
Compass Pathways is set to release pivotal Phase 3 COMP360 data in treatment-resistant depression. Find out why this readout could reshape psychedelic drug development.